First Midwest Bank Trust Division lifted its stake in shares of Pfizer, Inc. (NYSE:PFE) by 0.3% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 104,265 shares of the biopharmaceutical company’s stock after buying an additional 292 shares during the period. First Midwest Bank Trust Division’s holdings in Pfizer were worth $3,502,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the company. Kinsight LLC increased its holdings in shares of Pfizer by 1.9% during the second quarter. Kinsight LLC now owns 10,528 shares of the biopharmaceutical company’s stock worth $354,000 after buying an additional 198 shares in the last quarter. Gilman Hill Asset Management LLC increased its holdings in shares of Pfizer by 0.3% during the second quarter. Gilman Hill Asset Management LLC now owns 137,773 shares of the biopharmaceutical company’s stock worth $4,628,000 after buying an additional 359 shares in the last quarter. Greylin Investment Mangement Inc. increased its holdings in shares of Pfizer by 7.3% during the second quarter. Greylin Investment Mangement Inc. now owns 57,748 shares of the biopharmaceutical company’s stock worth $1,940,000 after buying an additional 3,922 shares in the last quarter. OLD Second National Bank of Aurora increased its holdings in shares of Pfizer by 0.8% during the second quarter. OLD Second National Bank of Aurora now owns 115,855 shares of the biopharmaceutical company’s stock worth $3,891,000 after buying an additional 908 shares in the last quarter. Finally, Argus Investors Counsel Inc. increased its holdings in shares of Pfizer by 6.1% during the second quarter. Argus Investors Counsel Inc. now owns 128,787 shares of the biopharmaceutical company’s stock worth $4,326,000 after buying an additional 7,382 shares in the last quarter. Institutional investors own 69.00% of the company’s stock.

PFE has been the subject of several research analyst reports. Cowen and Company set a $43.00 price target on shares of Pfizer and gave the stock a “buy” rating in a report on Monday, July 10th. Sanford C. Bernstein set a $39.00 price target on shares of Pfizer and gave the stock a “buy” rating in a report on Monday, July 17th. UBS AG reiterated a “buy” rating and set a $38.00 price target on shares of Pfizer in a report on Monday, July 31st. BMO Capital Markets reiterated a “buy” rating and set a $37.00 price target on shares of Pfizer in a report on Wednesday, September 6th. Finally, ValuEngine downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and eleven have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $38.04.

In related news, insider Sally Susman sold 38,230 shares of the business’s stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $35.00, for a total transaction of $1,338,050.00. Following the transaction, the insider now owns 145,649 shares in the company, valued at $5,097,715. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Alexander R. Mackenzie sold 15,000 shares of the business’s stock in a transaction dated Monday, August 7th. The shares were sold at an average price of $33.50, for a total transaction of $502,500.00. Following the transaction, the insider now owns 151,474 shares in the company, valued at approximately $5,074,379. The disclosure for this sale can be found here. Insiders sold 464,521 shares of company stock worth $15,813,961 in the last 90 days. Corporate insiders own 0.06% of the company’s stock.

Shares of Pfizer, Inc. (NYSE:PFE) traded down 0.03% during mid-day trading on Friday, reaching $35.96. 14,605,376 shares of the company’s stock were exchanged. Pfizer, Inc. has a one year low of $29.83 and a one year high of $36.12. The stock has a market cap of $213.87 billion, a PE ratio of 26.31 and a beta of 1.00. The company has a 50 day moving average price of $33.78 and a 200-day moving average price of $33.53.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.65 by $0.02. Pfizer had a net margin of 15.84% and a return on equity of 24.51%. The firm had revenue of $12.90 billion for the quarter, compared to analysts’ expectations of $13.08 billion. During the same quarter in the previous year, the company earned $0.64 earnings per share. The company’s revenue for the quarter was down 1.9% compared to the same quarter last year. On average, analysts predict that Pfizer, Inc. will post $2.56 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This report was first published by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another website, it was copied illegally and reposted in violation of U.S. and international copyright and trademark law. The original version of this report can be read at https://www.watchlistnews.com/pfizer-inc-pfe-shares-bought-by-first-midwest-bank-trust-division/1583284.html.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.